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Abstract
Background: Although some emergency department risk stratification tools consider
non-specific ECG findings as an aid in disposition decisions, their clinical value in
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patients with an initially low high-sensitivity cardiac troponin I (hsTnI) is unclear.
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Objective: Our purpose was to determine if non-specific ECG (ns-ECG) findings are
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associated with 30-day major adverse cardiac events (MACE) in ED patients presenting
with suspected acute coronary syndromes (ACS) who have a low initial hsTnI.
Methods: Using the prospective Siemens Atellica hsTnI Food and Drug Administration submission observational database, we conducted a retrospective cohort study of

SUNY Stony Brook, Stony Brook, New York,
USA

the association between ns-ECG findings (defined as left bundle branch block [LBBB],
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dial infarction, heart failure hospitalization, or coronary revascularization). Eligible

ST depression [STD], or T-wave inversions [TWI]) and 30-day MACE (death, myocarpatients presented with suspected ACS to one of 29 US EDs from April 2015 to
April 2016, had stable vital signs, a blood sample for hsTnI (Siemen’s Atellica, Siemens
Healthineers, Inc, Malvern, PA) obtained at 1, 3, and 6 hours after ED presentation, and
were followed for 30 days. The relationship between 30-day outcome, initial hsTnI, and
ns-ECG was evaluated using chi-square testing.
Results: Of 2676 enrolled, 1313 patients met the inclusion criteria and are included in
the analysis. Median (interquartile range) age was 62 years (54, 72), 54% were male,
with 56% white, and 39% African American. Median (interquartile range) times from
symptom onset to presentation and presentation to specimen collection were 92 (0,
216) and 146 (117, 177) minutes, respectively. The most common presenting symptoms were chest pain (84%), followed by dyspnea (9%). ECG findings were categorized
as T-wave inversion or non-specific T wave changes (42%), ST depression ns-ECG ST
changes (16%), or LBBB (2%). Thirty-day MACE occurred in 72 (5.5%) patients, with
coronary revascularization (35 patients, 2.7%) and heart failure (25 patients, 1.9%)
being the most frequent outcomes. In patients with an initial hsTnI below the limit of
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quantitation (LOQ) of 2.5 ng/L (n = 449), there was no association between ns-ECG
changes and 30-day MACE (P = 0.42). If the hsTnI was ≥LOQ (2.5 ng/L), there were
increased rates of 30-day MACE and ns-ECG findings (P = 0.01).
Conclusion: In ED suspected ACS patients without unstable vital signs, and an initial
hsTnI less than the LOQ (2.5 ng/L), ns-ECG findings are not associated with 30-day
major adverse cardiac events. The use of ns-ECG findings in ACS disposition should be
considered in the context of hsTnI levels.
KEYWORDS

ACS, Emergency, High-sensitivity cardiac troponin, hsTnI, LBBB, MACE, non-specific ECG
findings, ST depressions, T-wave inversions

1

INTRODUCTION

ated with adverse 30-day outcomes in suspected ACS patients with
initial low troponin levels compared with those with higher levels, as

1.1

Background

measured by a hsTnI assay in ED patients presenting with suspected
ACS.

Non-specific ECG (ns-ECG) findings are commonly defined as STsegment depression, T-wave inversion, and left bundle branch block
(LBBB).1 These changes are frequently included in risk stratification

2

METHODS

tools that often result in further evaluation and potential hospitalization. ns-ECG findings are included as an important constituent of the

2.1

Study design and setting

HEART score (history, ECG, age, risk factors, and initial troponin), a
tool that is commonly used as an aid in disposition decision making

Using data from High-Sensitivity Cardiac Troponin I Assays in the

for ED patients presenting with symptoms suggestive of acute coro-

United States (HIGH-US) Food and Drug Administration (FDA) submis-

nary syndromes (ACS). For example, when using the HEART score in

sion database,8 the FDA clearance trial of the Siemens Healthineers

an ED patient older than 65 years, ns-ECG findings would place the

Atellica hsTnI assay, we performed a retrospective observational

patient in the “not low risk” category, as they are reported to be associ-

cohort study to evaluate the association between ns-ECG changes

ated with a major adverse cardiac event (MACE) rate of 12%–16.6%.2,3

and 30-day MACE in patients with low presenting hsTnI concentra-

(Supporting Information)

tions. MACE was defined as death, myocardial infarction, heart failure
hospitalization, or undergoing coronary artery catheterization with a
subsequent finding of a coronary artery obstruction exceeding 70%

1.2

Importance

and requiring coronary revascularization.
The HIGH-US study was a prospective observational study,

The association between ns-ECG findings and 30-day adverse events

enrolling 2676 patients over 22 years of age, from 29 US centers, who

is poorly documented in the era of highly sensitive cardiac troponin

presented to the ED with angina or angina-equivalent symptoms, with

(hsTnI). Highly sensitive troponin assays have the advantage of detect-

blood drawn for troponin testing within 1, 3, and 6 hours after ED

ing lower concentrations than conventional troponin

testing.4

This

presentation, from April 2015 to April 2016. Patients were required

improved sensitivity may provide superior risk assessment, compared

to provide informed consent before enrollment and the protocol was

to ns-ECG findings, for predicting 30-day outcomes in patients pre-

approved by each contributing institution’s review board.

senting to the emergency department with suspected ACS given that

Inclusion criteria for this analysis were availability of documen-

hsTnI is independently associated with adverse cardiac outcomes in

tation of troponin results, ECG findings, and 30-day outcomes after

asymptomatic outpatient populations.5–7

ED encounter. Ns-ECG findings were defined as ST-segment depression (STD or non-specific ST-segment changes, T-wave inversion [TWI]
or non-specific T-wave changes, or left bundle branch block [LBBB])

1.3

Goals of this investigation

that was not classified as acute myocardial infarction (AMI) by the
treating clinical team. All ECGs were interpreted by board certified

We hypothesize that ns-ECG findings have a limited association with

cardiologists, blinded to the assay results and clinical course.

short-term MACE outcomes in the setting of a symptomatic ED patient

Patients were excluded for absent data, the presence of ECG

with a low hsTnI concentration that is below the limit of quantification

changes specific for cardiac pathology as the reason for presenta-

(LOQ). Our purpose was to determine if ns-ECG changes are associ-

tion, or hemodynamic instability. ECGs changes specific for cardiac
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The Bottom Line
In this paper, we evaluate whether non-specific ECG findings
in patients presenting with chest pain or its equivalent who
have low high-sensitivity troponin have any association with
short-term mortality. Our findings revealed that non-specific
ECG findings in the setting of a high-sensitivity troponin
below the limit of quantification are not associated with 30day major adverse cardiac events. This is significant because
it may help reduce the burden on both the health care system,
and more important, the patients themselves as they can be
further evaluated for these findings in an outpatient setting
rather than needing to be admitted to the hospital for further
workup of such findings.

pathology were defined as ST segment elevation MI, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular tachycardia,
ventricular-paced rhythm, supraventricular tachycardia, and complete heart block. Hemodynamic instability was defined as heart
rate > 120 bpm or systolic blood pressure <90 mmHg at ED presentation. The primary outcome of interest of this analysis is the
development of any MACE within 30 days of ED presentation.

2.2

Data collection

Blood samples were collected in lithium heparin and serum blood tubes
and analyzed at core labs for research purposes (Siemens Healthcare Diagnostics, Tarrytown, NY; Research & Development Institute,
Calabasas, CA; Baylor Scott & White Healthcare Texas A&M Health
Science Center, Temple, TX; University of Maryland, Baltimore, MD;
or Minneapolis Medical Research Foundation, Minneapolis, MN) on
the Atellica Immunoassay Analyzer and ADVIA Centaur XP systems.
The Atellica Immunoassay hs-cTn assay is a 3-site sandwich immunoassay that uses direct chemiluminescent technology and has a measuring
range of 2.5–25,000 ng/L, a limit of detection of 1.6 ng/L, and limit of
quantitation of 2.5 ng/L. The 10% coefficient of variation is found at
6 ng/L, and the 99th percentile upper reference limit (URL) is 45 ng/L,
with sex-specific 99th percentile URLs of 34 and 53 ng/L, for women
and men, respectively.9–11

F I G U R E 1 Study flow chart. Abbreviations: CHB, complete heart
block; LBBB, left bundle branch block; LVH, left ventricular
hypertrophy; RBBB, right bundle branch block; STD, ST-segment
depression; STEMI, ST-segment elevation myocardial infarction; SVT,
supraventricular tachycardia; TWI, T-wave inversion; VT, ventricular
tachycardia

3

RESULTS

A total of 1313 patients met all inclusion, and no exclusion, criteria for
this analysis (Figure 1). Median (interquartile range [IQR]) time from
symptoms onset to ED presentation was 92 minutes (0, 216), and the
median (IQR) duration between presentation to sample collection was
146 minutes (117,177). Descriptive statistics of this cohort are summarized in Table 1. Median (IQR) age was 62 years (54, 72), 54% were
male, 56% and 39% were white and African American, respectively.
The most common chief complaint was chest pain (n = 1101, 84%)
followed by dyspnea (9%). ECGs were interpreted as normal in 525
(40%), with non-specific findings in the majority (Table 1). Coronary
artery disease (CAD) risk factors were most commonly hypertension
(n = 916, 69.8%) and hyperlipidemia (n = 552, 42%) (Table 1). Overall,
more than one third (n = 472, 36%) of patients had established CAD;

2.3

Analysis

272 (21.7%) had a prior MI, 330 (25.1%) had a previous percutaneous
coronary intervention, and 105 (8%) had a history of coronary artery

Unadjusted comparison between groups was accomplished using the

bypass grafting.

Mann–Whitney U test for continuous variables and the Pearson χ2

A total of 449 had an initial concentration <2.5 ng/L and 864

statistic for categorical variables. The association between ns-ECG

patients had an initial troponin ≥2.5 ng/L. Overall, 72 patients had

findings on the initial ECG stratified by the initial hsTnI with 30-day

MACE within 30 days of presentation; 17 (3.8%) and 55 (6.4%) and in

MACE, was evaluated using χ2 test. Alpha was defined as P < 0.05. All

the <2.5 and ≥2.5 ng/L hsTnI groups, respectively (Table 2A,B). There

statistical analyses were performed using the SAS 9.4 software (SAS

were differences in baseline characteristics between those with higher

Institute Inc, Cary, NC, 2014). Graphs were generated using Microsoft

initial hsTnI, defined as ≥2.5 ng/L, versus those below. Patients with

Excel 2020 (Redmond, WA) version 16.41.

a higher troponin were older, had a median (IQR) age of 64 (56, 74)
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Baseline characteristics of study population

Demographics

No. (%)

HsTnI ≥LOQ
(2.5 ng/L)

HsTnI <LOQ
(2.5 ng/L)

n = 1313

n = 864 (%)

n = 449 (%)

64 (56, 74)

58 (50, 66)

<0.001

Age, median (IQR), y
Age, y

62 (54, 72)

18–34

16 (1)

35–49

185 (15)

50–59

388 (32)

60–69

374 (30)

70–79

175 (14)

80 and above

92 (7)
<0.001

Sex
Female

608 (46)

336 (39)

271 (61)

Race

0.318

White

734 (56)

468 (54)

266 (59)

Black

518 (39)

359 (42)

159 (35)

American Indian

16 (1)

9 (1)

7 (2)

Asian

6 (1)

17 (1)

11 (1)

Hawaiian

1

1

0

All other

27 (2)

16 (2)

11 (2)

1101 (84)

704 (81)

397 (88)

Dyspnea

119 (9)

94 (11)

25 (6)

Dizziness

19 (1)

14 (2)

5 (1)

8 (1)

4

4 (1)

Chief complaint
Chest pain

Palpitations
Fatigue
Other, non-specific

0.013

3

3

0

63 (5)

45 (5)

18 (4)
<0.001

ECG findings
Normal
Left bundle branch block

525 (40)

277 (32)

248 (55)

26 (2)

21 (2)

5 (1)

ST-segment depression or non-specific ST changes

206 (16)

162 (19)

44 (10)

T-wave inversion or non-specific T-wave changes

556 (42)

404 (47)

152 (34)
<0.001

Risk factors and comorbidities
Hypertension

916 (69.8)

659 (8)

257 (57)

Hyperlipidemia

552 (42)

406 (47)

146 (33)

Heart failure

232 (17.7)

197 (23)

35 (8)

Diabetes mellitus

400 (30.5)

298 (34)

102 (23)

Coronary artery disease

472 (36)

364 (42)

108 (24)

272 (21.7)

212 (25)

60 (13)

Prior PCI

330 (25.1)

262 (30)

68 (15)

Prior CABG

105 (8)

88 (10)

17 (4)

139 (10.6)

122 (14)

17 (4)

49 (3.7)

42 (5)

7 (2)

81 (9)

37 (8)

Prior MI

Chronic kidney disease
Peripheral vascular disease

P value

Stroke

118 (9)

Tobacco use

391 (29.8)

254 (29)

137 (31)

Current

383 (29.2)

264 (31)

119 (27)

Former
Abbreviations: CABG, coronary artery bypass graft; HsTnI, high-sensitivity cardiac troponin I; IQR, interquartile range; LOQ, limit of quantitation; MI,
myocardial infarction; PCI, percutaneous coronary intervention
P < 0.05 is considered statistically significant.
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TA B L E 2 30-day outcomes, stratified by ECG and hsTnI. Relation
of ECG and 30-day MACE if hsTnI < 2.5 ng/L (A); Relation of ECG and
30-day MACE if hsTnI ≥2.5 ng/L (B); Relation of 30-day MACE and
hsTnI if abnormal ECG (C)

Non-specific ECG changes were common, with T-wave inversions
or non-specific T-wave changes comprising the majority of abnormal
ECG findings (42%). This compared to ST-segment depression or nonspecific ST changes, which constituted only 16%. Last, only 2% of the
participants had ECG findings of LBBB.

A

Overall, there was an association between initial hsTnI concentraIn cohort with hsTnI <2.5 ng/L

tion and 30-day MACE (P < 0.001). There was also an association

30-day MACE
ECG findings

Yes (%)

Non-specific

6 (3)

between abnormal ECG findings, specifically LBBB, STD, and TWI, and
No (%)

Total

30-day MACE with 6.6% of patients with ns-ECG findings having a

195 (97)

201

MACE within 30 days of follow up, versus 3.8% of those with a normal
ECG (P = 0.03).

Normal

11 (4.4)

237 (95.6)

248

Total

17

432

449

Additionally, patients with non-specific ECG findings had an association between hsTnI and 30-day MACE (P = 0.0168) [Table 2C].

B

However, stratifying by the initial hsTnI found the association between

In cohort with hsTnI ≥2.5 ng/L

the initial ns-ECG findings and 30-day MACE was significant only

30-day MACE

if the hsTnI was ≥2.5 ng/L (30-day MACE = 7.8% vs 3.2%, in those

ECG findings

Yes (%)

No (%)

Total

with non-specific vs normal ECGs, respectively, P = 0.010) and

Non-specific

46 (7.8)

541 (92.2)

587

insignificant below this level (3% vs 4.4%, respectively, P = 0.42).

9 (3.2)

268 (96.8)

277

Normal
Total

55

809

864

Of patients with a hs-cTnI ≥2.5 ng/L, the odds of having nonspecific ECG changes were 2.53 times higher among those whho
had 30-day MACE than those who did not have any significant

C

short-term MACE. In those with the hs-cTnI below 2.5 ng/L (odds
In cohort with abnormal ECG

ratio [OR] = 2.53, 95% confidence interval [CI]:1.22, 5.25), the odds

30-day MACE

of having non-specific ECG changes were 0.34 times lower among

hsTnI

Yes (%)

No (%)

Total

those who had 30-day MACE than those who had not (OR = 0.66,

hsTnI >= 2.5 ng/L

46 (7.8)

541 (92.2)

587

96% CI: 0.24, 1.82).

6 (2.9)

195 (97.1)

201

736

788

hsTnI < 2.5 ng/L
Total

52

There was no significant difference in proportion of males (62%)
with non-specific ECG compared to females (57%, P = 0.06). However,
there were significant differences between sexes when evaluating the

Abbreviations: HsTnI, high-sensitivity cardiac troponin I; MACE, major
adverse cardiac events

association between non-specific ECG findings and adverse outcomes
when the initial hsTnI ≥2.5 ng/L. Whereas males with higher hsTnI and
ns-ECG findings were more likely to have 30-day MACE (P = 0.01)

TA B L E 3

women were not (P = 0.77).

30-day MACE rate by hsTnI level

30-day events, N (%)a

HsTnI < LOQ
(< 2.5 ng/L)
n = 17 (%)

There was a total of 3 deaths reported, and all were associated
HsTnI ≥LOQ
(2.5 ng/L)
n = 60 (%)

with a hsTnI > 45 ng/L. One was attributed to end-stage lung cancer,
a second to an unknown cause, and the third was cardiac related. The
cardiac death patient had concomitant ns-ECG ST-segment changes

Death

0 (0)

3 (0.35)

Acute myocardial infarction

1 (0.2)

8 (0.9)

Coronary revascularization

10 (2.2)

25 (2.9)

When examining patients with 30-day MACE based on specific

Heart failure hospitalization

6 (1.3)

19 (2.2)

ECG changes (n = 72), it was found that 37 (51.4%) had T-wave

a

Numbers do not sum as patients could have multiple events
Abbreviations: HsTnI, high-sensitivity cardiac troponin I; LOQ, limit of
quantitation; MACE, major adverse cardiac events

and inverted T-waves on the ECG, and the other 2 deceased patients
had normal ECG findings.

inversions or non-specific T-wave changes. This comprised 6.7% of
the group with T-wave changes who suffered 30-day MACE (1 death,
6 AMI, 14 heart failure hospitalization, and 16 with CAD requiring
revascularization). Similarly, 6.3% of the cohort with ST-segment
depression or non-specific ST changes had 30-day MACE (5 heart fail-

versus 58 (50, 66) years, and were more likely male, 61% versus 39%,

ure hospitalizations and 8 CAD requiring revascularization), whereas

respectively, compared to the low hsTnI group. The patients in the high

only 2 with LBBB experienced 30-day MACE. However, given the

hsTnI group were also less likely to have normal ECG findings; 32% vs

small LBBB cohort (n = 26), this comprised 7.7% of this group (1

55% when compared to the low hsTnI population. Finally, patients with

AMI, 1 heart failure hospitalization). Conversely, only 3.8% of those

hsTnI <2.5 ng/L had a MACE rate of almost half of those in the higher

with normal ECG findings had 30-day MACE (2 deaths, 2 AMI, 5

troponin cohort, with each of the subcategories being consistently

heart failure hospitalization, 11 CAD requiring revascularization)

lower (Table 3).

[Figure 2].
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70.0

highly sensitive troponin testing results. In fact, Mahler et al. reported

60.0

no difference in the performance of the HEART score when using either

50.0

conventional cardiac TnI or hsTnI. They showed that incorporating
either assay achieved 100% sensitivity and negative predictive value.12

40.0

However, as sensitivity is a function of false negatives, it can be maxi30.0

mized simply by excessive admission rates (eg, a 100% ED admission

20.0

rate results in no false negative discharges).

10.0

Other analyses have demonstrated that, although the HEART score

0.0

can identify a cohort of patients who are safe discharge candidates,

TWI or nonspecific STD or nonspecific

LBBB

Normal ECG

ECG Findings
CAD

AHF

AMI

Death

F I G U R E 2 30-day MACE by ECG findings. Abbreviations: AHF,
acute heart failure; AMI, acute myocardial infarction; CAD; coronary
artery disease; LBBB, left bundle branch block; STD, ST-segment
depression; TWI, T-wave inversion

scoring systems that do not weigh ns-ECG parameters (eg, ED ACS
score) are more effective at maximizing the safe discharge rate.13,14
These findings are consistent with our data that demonstrate hospitalization based on isolated ns-ECG changes, although expensive, would
be associated with minimal outcome changes.15
Our study shows that non-specific ECG changes are not associated with short-term adverse cardiac outcomes in the setting of a
hsTnI < LOQ (2.5 ng/L). Hemodynamically stable patients who present
within 3 hours of symptom onset have non-specific findings on initial

3.1

Limitations

ECG, and have an initial hsTnI level of <LOQ (2.5 ng/L) obtained
within 2–3 hours after presentation are safe to discharge home from

This was a retrospective study that included 29 different sites, and

the ED and can be provided with outpatient follow-up for further

although large, a prospective validation will be needed before patient

workup.

management should be universally altered based on these results.

LBBB has historically been regarded as a STEMI equivalent and

Usual care workups were dictated by contemporary generation tro-

can be concerning for a serious underlying myocardial injury. This is

ponin assays, and thus there is the potential to identify more or less

especially true if it is new, or presumably new, and associated with

MACE using hsTnI assays, which could affect our findings. Additionally,

concerning clinical symptoms. However, the prognostic value of the

the individual parameter definition of non-specific ECG changes is not

presence of a LBBB is unclear. Jain et al reported that one third

standardized, and institutional variation may have occurred. How the

of patients diagnosed with new, or presumably new, LBBB had non-

differential interpretation (the way one physician defines non-specific

cardiac final diagnoses, which was particularly seen in younger patients

T-wave changes vs another) could affect our results is unclear. Further-

with low cardiac risk scores, low troponin, and ECG Sgarbossa score

more, although it is unclear if ST-elevation MI (STEMI) equivalents such

of zero.16 Studies have been inconsistent with regard to its predictive

as deWinter’s T-waves or Wellen’s morphology were accounted for,

value for mortality and morbidity, as some regarded the LBBB as an

because of the very low MACE rate in the < 2.5 ng/L troponin group,

independent predictor, whereas others have found it to be attributed

the clinical impact of a potential misclassification is minimal. Finally,

to other confounders.17–20 We hypothesize that LBBB in the setting of

another limitation to generalizing our data is that troponin assay cut-

a low hsTnI is low risk, with limited association with short-term MACE,

points are not universal and cannot be considered for assays other than

as highly sensitive biomarkers such as hsTnI are able to detect mini-

the Siemens Healthineers Atellica hsTnI.

mal myocardial injury. However, because of the smaller proportion of

Further studies are needed, particularly in the United States, which

our patients having LBBB (only 2%) our results may not be general-

has been slow to adopt highly sensitive troponins on a widespread

izable to patients with this specific finding. Furthermore, ECGs with

scale, to evaluate the validity of these findings and to determine the

LBBB should be interpreted based on modified Sgarbossa criteria to

most accurate cutoffs to incorporate into risk stratification scores

indicate the presence of AMI that, if present, would require the activa-

among the US population.

tion of the cardiac lab.21 It is unclear whether Sgarbossa criteria were
considered when recording these findings by each of our respective
facilities.22 Thus, we suggest caution when considering our findings to

4

DISCUSSION

this particular group.
Sex differences were also noted in our analysis. Males were more

Our data are the first to demonstrate that highly sensitive troponins

likely to have 30-day MACE, despite having no difference in the

have greater prognostic value than isolated ns-ECG changes. Thus,

frequency of non-specific ECG changes. Mosca et al. reported that,

when faced with ns-ECG changes and a very low hsTnI, the clinician

although a higher proportion of females have cardiovascular disease,

may consider the hsTnI concentration as more indicative of 30-day

strokes, and subsequent mortality, the case is reversed with regard to

prognosis. Although others have evaluated ns-ECG changes, when

CAD, where males constitute a higher proportion of those affected

combined in a risk stratification score (eg, the HEART score), they

by adverse outcomes.23 Further studies are needed to explain this

have not evaluated this as an individual outcome predictor stratified by

disparity.
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The United States has not universally implemented the use of highly

cope Inc, Brainbox Inc, Braincheck Inc, Coagulo Inc, Comprehensive

sensitive troponin assays, potentially owing to concerns of greater cap-

Research Associates LLC, Comprehensive Research Management Inc,

ture of type 2 MI and overdiagnosis. However, the greatest utility of

Emergencies in Medicine LLC, Fast Inc, Forrest Devices, Ischemia

hsTnI is in the ED setting, where it can rapidly rule out ACS. Its great-

DX LLC, Lucia Inc, Prevencio Inc, ScPharma, Trivirum Inc, Upstream

est value is its incorporation into protocols that do not necessitate as

Inc. Christopher R. deFilippi: Research funding to Inova fromAb-

much as 6 hours to determine whether a low-risk chest pain patient

bott Diagnostics, Roche Diagnostics, Siemens Healthineers, and Ortho

is safe for discharge. The ability of hsTnI to expedite the process to a

Diagnostics, and consults for FujiRebio, Roche Diagnostics, Siemens

1 hour rule-out protocol reduces unnecessary resource use, shortens

Healthineers, and Ortho Diagnostics. James McCord: Research Sup-

ED length of stay, and may reduce ED overcrowding.24 Furthermore,

port: Beckman, Abbott, Siemens, Roche. Consulting: Beckman, Roche.

even greater ED impact is expected, given the potential for highly sen-

Richard Nowak: The author has no disclosures to report. Robert H.

sitive troponins to enter the point-of-care market in the very near

Christenson: Consultant: Roche Diagnostics, Siemens Healthineers,

future.

Quidel Diagnostics, Sphingotech, Becton Dickinson, Beckman Coul-

Patients with STEMI were excluded from this study. In this popu-

ter. Scientific Advisory Board: Roche Diagnostics, Siemens Healthi-

lation, recent data showed a possible delay in the rise of hsTnI that is

neers, Quidel Diagnostics, Sphingotech, Becton Dickinson. Alexander

thought to be due to the complete vascular occlusion interfering with

T. Limkakeng: Research funding from the following entities: Roche

the release of myonecrosis markers into the blood stream. According

Diagnostics, Inc., Abbott Laboratories 2020-now, Siemens Health-

to Wereski et al., a small percentage of confirmed STEMI cases had a

care Diagnostics until 2020, Bristol Meyers Squibb 2019–2020, GE

hsTnI level of <5 ng/L (Abbott Architect Stat assay) upon presentation

2019—2020, Astrazeneca 2019—2020, Forest Devices, Inc: 2019—

to the ED, which was more commonly seen in patients with posterior

2020, Department of Defense/Henry Jackson Foundation, National

STEMI.25

Institutes of Health, Regeneron, Becton Dickinson.

Finally, our data incorporate a patient population with a mean age
exceeding 60, and who commonly have multiple comorbidities such
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